AN INNOVATIVE REPURPOSING OF MEfloquine; ASSESSMENT OF ITS THERAPEUTIC EFFICACY IN TREATING Cryptosporidium parvum INFECTION OF BOTH IMMUNOCOMPETENT AND IMMUNOCOMPROMIZED MICE

By

NAGWA SHAABAN ALy1*, RABAB FAWZY SELEM1, RABAB SAYED ZALAT2, HEBA KHALIL3 AND BOSHRA EL-SAYED TALHA HUSSIEN4

Department of Parasitology1, Faculty of Medicine, Benha University1, Benha 13518 And Departments of Parasitology4 and Pathology3, Theodore Bilharz Research Institute, Imbaba P. O. Box 30, Giza, and Department of Tropical Medicine4, Tanta Faculty of Medicine, Tanta University, Egypt (*Correspondence: drnagwashaban@gmail.com)

Abstract

Cryptosporidium parvum is a protozoan parasite can affect humans, worldwide, causing asymptomatic infections or diarrheal disease, which may be life-threatening in immunocompromised and neonatal individuals. Mefloquine is one of the most promising anti parasitic drugs. The present report aimed to study the in-vivo efficacy of Mefloquine when applied in immunocompetent and immunocompromised cryptosporidiosis-infected mice. One week post infection, treated groups received either Nitazoxanide (100 mg/Kg daily for 5 days) or single dose of mefloquine (400 mg/Kg). Two weeks post treatment, all mice were sacrificed. Stool samples and intestinal histopathology were examined. For both drugs, immunocompetent groups showed better parasitological clearance than immunocompromized one. The Cryptosporidium oocyst reduction rates with Nitazoxanide (NTZ) and Mefloquine were 53.3%, and 61.6% respectively in the immunocompetent groups. The corresponding rates in immunocompromised groups were 49.93% and 60.03% for NTZ and mefloquine respectively. A single dose of mefloquine treatment (400mg/kg) resulted in higher oocyst reduction rates than the classic approved anti cryptosporidiosis drug (Nitazoxanide with five days application regimen). The histopathological study supported the parasitological findings as mefloquine treated mice tissue showed mild to moderate inflammatory changes while that of other groups ranged from moderate to severe alterations in the mice tissue. These results suggested that mefloquine which is FDA approved, already marketed and commercially available on a global scale has an excellent anti parasitic activity against Cryptosporidium parvum infection with single dose application; which saves time, cost and efforts to search for additional or alternative drugs for treating cryptosporidiosis. More large scale studies are needed to illustrate its dose response relationship using multiple doses regimens, performance and limitations on immunocompromized population, synergistic effect with already approved drugs, mechanism of action on Cryptosporidium parasite and its possible role in chemoprophylaxis specially for high risk individuals.

Key words: Egypt, Cryptosporidium parvum, Mefloquine, Nitazoxanide, In-Vivo.

Introduction

Cryptosporidium parvum is an internationally distributed protozoan parasite that is existed in both vertebrates and invertebrates (Lima et al, 2011). Infections are transmitted by the fecal–oral route, or through contaminated food or water, and many major waterborne outbreaks have occurred (Yoder and Beach, 2010). Cryptosporidiosis represents a foremost health problem as it is a frequent cause of diarrhea in both immunocompetent and immunodeficient individuals (Rossignol, 2010), all over the world (Yoder et al, 2012; Insulander et al, 2013). Nitazoxanide is the only approved drug for treatment of diarrhea caused by Cryptosporidium infection (Mainali et al, 2013). But, it showed imperfect efficacy in the most vulnerable patients (Amadi et al, 2002; Abubakar et al, 2007; Manjunatha et al, 2016). Besides, the dependence of a one drug as sole effective treatment for any microorganism is known to carry an inevitable risk of electing resistant strains and failure of treatment. Hence, development of new effective drug for cryptosporidiosis represents a pressing
need. Drug repurposing (also termed re-profiling, re-tasking, therapeutic switching or drug repositioning) is the process of developing new indications for existing, failed or abandoned drugs or advanced clinical candidates (Sekhon, 2013). Drug repurposing is a useful strategy to accelerate the drug development process due to lower costs, reduced risk and decreased time to market due to availability of preclinical data (Padhy and Gupta, 2011). This enables not only pharmaceutical companies but also public-sector researchers to engage in drug discovery and development efforts (O’Connor and Roth, 2005), and hence might result in treatment options for diseases almost exclusively addressed by public sector researchers, such as the neglected tropical diseases. Mefloquine is a 4-quinolinemethanol synthetic antimalarial analogue of quinine developed in 1971 (Kumar et al., 2009). Many years later, it proved to be more than antimalarial drug as it revealed excellent antiparasitic activities including antischistosomal activity (Keiser et al, 2010; Ingram et al, 2012; Basra et al, 2013; Xiao et al, 2013; Abou-Shady et al, 2016). Besides its antischistosomal activity, Keiser et al. (2010) reviewed the effectiveness of mefloquine against foodborne trematodes and highlighted that mefloquine is not active against F. hepatica nor C. sinensis, but interestingly was active against juvenile and adult O. viverini in a hamster infection (Keiser et al, 2009a). However, mefloquine failed to produce an effect against O. viverini in clinical trials (Soukhathammavong et al, 2011). In other study, mefloquine yielded significant results against C. sinensis infection in a rat model and Paragonimus westermani infection in a dog model, but the results were not better than a treatment with praziquantel (Xiao et al., 2010). Also, mefloquine proved activity against Babesia (Munkhjargal et al, 2012) Echinococcus multilocularis (Küster et al, 2015) and adult Fasciola gigantica (Shalaby et al, 2016).

The aim of this study was to explore the efficacy of mefloquine against cryptosporidiosis infection in a controlled study including both immunocompetent and immunocompromized mice.

Materials and Methods

This study was carried out on laboratory bred Swiss albino female mice (n = 80) weighing approximately 20g. They were categorized into the following 8 groups of 10 mice each: group I: Immunocompetent, infected non treated mice, GII: Immunocompetent, infected animals treated with nitazoxanide orally 100mg/kg (Li et al, 2003) daily for five consequent days, one week post infection, GIII: Immunocompetent- infected mice treated with mefloquine orally 400mg/Kg single dose (Keiser et al, 2009b), a week post infection. GIV: Immunocompetent, non-infected non treated, GV: Immunocompromised, infected non treated mice, GVI: Immunocompromised, infected animals treated with nitazoxanide orally (0.04mg/mouse/day) daily for five consequent days, a week post infection, GVII: Immunocompromised, infected mice treated with mefloquine orally 400mg/ Kg single dose, one week post infection and GVIII: Immunocompromised, non-infected non-treated. Animals were sacrificed two weeks post treatment.

Immunosuppression was performed by giving the animals synthetic corticosteroids (dexamethasone) orally at a dose of 0.25 mg/g/day for 14 successive days prior to inoculation with Cryptosporidium oocysts (Rehg et al, 1988). Cryptosporidium oocysts were obtained from naturally infected calves (from slaughter houses) by collection of scrapings of the ileal mucous membrane and fecal content (Anderson, 1985). The samples were examined for confirmation of the presence of oocysts by modified Ziehl-Neelsen staining method (Henriksen and Pohlen, 1981). The infective samples were preserved by mixing with an equal volume of 2.5% potassium dichromate (K2Cr2O7), after Campbell and Current.(1983). The infective
inoculums were prepared (Reese et al., 1982) and the number of oocysts in the concentrated stock inoculum was counted to determine how much fluid volume is the inoculums per mouse.

All mice in the studied groups except the control groups were infected orally with the prepared inocula of Cryptosporidium oocysts; this occurred on day 15 of dexamethasone in the immunosuppressed groups (Moon et al., 1982). The animals were deprived of water overnight, and were then inoculated intra-esophagally with the prepared inoculums using a tuberculin syringe connected to a polythene tube. The amount given to each mouse was adjusted to contain approximately 1000 oocysts/mouse (Gaafar, 2007). Two weeks post-treatment, all mice were scarified. Stool samples and intestinal histopathology were examined. Mefloquine hydrochloride (Lariam 250mg tablets) was obtained from ROCH Co. Nizatrazoxanide (Nanazoid100mg) was provided by Medizen Pharmaceutical industries for Utopia Pharmaceutic.

Assessment of infection and the drug effect: 1- Stool examination: Fresh fecal pellets from each mouse in the study groups were collected separately. Each sample was suspended in 10% formalin and homogenized. Then, 1 mg was prepared as a fecal smear and stained by the modified Ziehl-Neelsen staining method. The stained fecal smear was examined microscopically and the number of oocysts was counted in 10 high-power fields (Mohamed et al., 2015).

2- Histopathological examination: The terminal 2 cm of the ileum was submitted to routine histopathological processing at the Pathology Department, TBRI, where they were fixed in 10% neutral buffered formalin, dehydrated in ascending grades of ethanol, followed by immersion in xylene, and then impregnated in paraffin. Two 5-mm thick sections were taken from each block. One section was stained with hematoxylin and eosin for evaluation, and then examined by light microscopy for assessing histopathological changes (Tzipori et al., 1981).

Statistical analysis: Data were collected, tabulated, and statistically analyzed using SPSS program version 11. ANOVA test was used for detection of variation between groups. Post hoc Bonferroni test was used for pair wise comparisons between groups. Unpaired Student t test was used to assess if the host immune status influenced the performance of studied drugs through comparing their mean oocyst count of immunocompetent and immunocompromized groups. The percentage infection reduction rate was assessed using the formula: (mean value of the infected untreated group - mean value of infected- treated group) x100/mean value of infected- untreated group (Abdel Salam et al., 2008). A p-value equal to or less than 0.05 was considered significant and less than 0.01 was considered highly significant.

Results

**Table 1:** Comparison between means of oocyst number in infected non-treated control, NTZ and Mefloquine treated immunocompetent mice groups.

<table>
<thead>
<tr>
<th>Oocyst count</th>
<th>infected control (N=10)</th>
<th>NTZ (N=10)</th>
<th>Mefloquine (N = 9)</th>
<th>P value</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean ±SD</td>
<td>33517.4 ± 5320.1</td>
<td>15636.3 ± 6300.4</td>
<td>12856.8 ± 3061.7</td>
<td>&lt;0.001</td>
<td>46.385</td>
</tr>
<tr>
<td>Range</td>
<td>24750–43333</td>
<td>1366.3–27000</td>
<td>8222.2–19200</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

There was a highly significant statistical difference between infected control group mean oocysts count and that of NTZ and mefloquine treated immunocompetent mice groups, though mefloquine ones showed an observably lower mean oocyst count which was reflected on the mean oocysts count reduction rate of both groups; 53.3% for NTZ group and 61.6% for mefloquine treated one . Pairwise comparison between various groups using Bonferroni post hoc test showed that there was no statistically significant difference between the mean Cryptosporidium oocysts count of NTZ and mefloquine treated immunocompetent mice P value= 0.750, denoting that mefloquine efficacy was comparable to that of NTZ with the upper hand for the earlier.
There was a highly significant statistical difference between infected control group mean Cryptosporidium oocysts count and that of NTZ and mefloquine treated immunocompromized mice groups, though mefloquine ones showed an observably lower mean oocysts count which was reflected on the mean oocyst count reduction rate of both groups; 49.9% for NTZ group and 60% for mefloquine treated one. Pairwise comparison between various groups using Bonferroni post hoc test showed that there was no statistically significant difference between the mean Cryptosporidium oocysts count of NTZ and mefloquine treated immunocompetent mice $P$ value=0.679, denoting that mefloquine efficacy was comparable to that of NTZ with the upper hand for the earlier.

<table>
<thead>
<tr>
<th>Immune status</th>
<th>NTZ</th>
<th>Mefloquine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean $\pm$SD</td>
<td>23511.99±8117.1</td>
<td>18767.6±5742.3</td>
</tr>
<tr>
<td>Range</td>
<td>3355.6–93000</td>
<td>10888.9–25600</td>
</tr>
</tbody>
</table>

Table 3: Comparison between NTZ and mefloquine in treating C. parvum infection by host immunity.

In NTZ and mefloquine treated mice, oocyst mean counts were substantially impacted by host immune status as they were significantly higher in immunocompromized groups treated by both drugs.

The histopathological examination in this study was performed just to roughly assess our hypothesis regarding the mefloquine anticytosporidal activity as manifested by the degree of inflammatory changes in small intestine tissue and not to measure its effect the on the intensity of infection. As seen in figures (1, 2, 3 & 4), the histopathological screening study results supported that of parasitological ones. The infected non treated samples showed sever villous atrophy and inflammatory cells infiltrations. There was a mild to moderate inflammatory reaction in mefloquine treated mice samples while the intensity of inflammation ranged from moderate to marked in the corresponding NTZ samples as compared with the control samples.

Discussion

Cryptosporidiosis may become life threatening which can lead to death in some individuals specifically children and immunosuppressed patients. There is no completely satisfactory treatment for cryptosporidial enteritis has been successfully developed (Castellanos-Gonzalez et al, 2016). Consequently, probing for an alternate effective therapy is a worthy research area. Mefloquine therapeutical efficacy has been proved for many other parasites (Xiao et al, 2010; Munkhjargal et al, 2012; Basra et al, 2013; Xiao et al, 2013; Küster et al, 2015; Shalaby et al, 2016; Abou-Shady et al, 2016), but up till now to our knowledge, there are no studies in the literature about repurposing it for treatment of Cryptosporidium parvum parasite infection. In this study, both NTZ and mefloquine treatment resulted in a partial parasitological clearance of subjected mice as manifested by the highly significant statistical difference between the mean C. parvum oocyst count in the treated groups as compared by the infected non treated one. These findings were valid for both immunocompetent and immunocompromized mice groups. In both NTZ and mefloquine treated mice the mean Cryptosporidium oocyst count was significantly higher in immunocompromized. Theoretically, this could be due to the logic profound replication of Cryptosporidium parasites happens as a result of dexamethazone induced immunosuppression so as to this enormous number exceeds the top limit of antiparasitic capabilities of both drugs and eventually mounting the parasite yield upon treatment. On the molecular level, the dexamethazone inhibitory effect on CD4 cells

Table 2: Comparison between means of oocyst number in infected non treated control, NTZ and Mefloquine treated immunocompromized mice.

<table>
<thead>
<tr>
<th>Oocyst count</th>
<th>Infected control (N=10)</th>
<th>NTZ(N=10)</th>
<th>Mefloquine (N=10)</th>
<th>$P$ value</th>
<th>$F$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean $\pm$SD</td>
<td>46973.95±11018</td>
<td>23511.99±8117.1</td>
<td>18767.6±5742.3</td>
<td>&lt;0.001</td>
<td>31.067</td>
</tr>
<tr>
<td>Range</td>
<td>34888.9–72000</td>
<td>13555.6–93000</td>
<td>10888.9–25600</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
numbers (Parimi et al., 1999) was substantially contributing to this finding as the ultimate control of Cryptosporidium parasite infection in adult mice is dependent on CD4+ T cells (Aguirre et al., 1994; Schmidt et al., 2001). Consequently, in face of this dexamethasone-induced CD4+ declining numbers, it seems that even potent antiprotozoal agents like NTZ and mefloquine cannot affect the parasite replicating and infecting activities as if the immune system is working properly. This agreed with Amadi et al. (2009) reported the attenuating effect of the immunosuppressed status caused by HIV infection in children on NTZ therapeutic efficacy, even after applying a high dose prolonged treatment regimen. Also, Amadi et al. (2002); Abubakar et al. (2007) and Manjunatha et al. (2016) demonstrated the NTZ inadequacy in presence of immunocompromization status. The therapeutic effect of NTZ on Cryptosporidium infection in mice was previously reported since long time by others (Theodos et al., 1998; Blagburn et al., 1998; Gargala et al., 2000). Interestingly, mefloquine treated mice showed a higher Cryptosporidium oocyst reduction rates than the NTZ in both immunocompetent and immunocompromised mice, though the difference was statistically insignificant, but in view of the difference in dosage regimen between mefloquine (single dose) and NTZ (five consequent doses), we can effortlessly expect much better performance for mefloquine if used in a repeated dosage system. Generally, the histopathological study results supported the parasitological data, in mefloquine treated groups it showed mild to moderate degree of intestinal tissue inflammation, while that of NTZ ranged from moderate to marked inflammatory changes. Being both protozoa, both belong to Apicomplexa Phylum; Sporozoa Class and Coccidia subclass, it could be hypothesized that the mechanism of mefloquine action on Cryptosporidium parasite might be related to that exerted by it on Plasmodium parasites. Plasmodium spp. could synthesize several species of sphingolipids (cell membrane component) and retrieve others from their host cells (Coppens, 2013). A pioneering study of the lipid content in P. falciparum-infected red blood cells reported a significant increase in the sphingomyelin content compared with uninfected red blood cells, probably owing to the parasite’s activities (Lawrence and Cenedella, 1969). Sphingomyelins are used by the parasite to form and stabilize a tubulovesicular network (TVN) of membranes that extends from the membrane of the parasitophorous vacuole to the erythrocytic plasma membrane (Haldar, 1996; Lauer et al., 1997). Studies on mefloquine mode of action reported that it acts through sphingomyelinase enzyme activation which leads to excess ceramide production (Olliaro and Wells, 2009) and decreased infectivity in vitro and in humans (Lauer et al., 2000, Grellepois et al., 2005; Pankova-Kholmyansky and Flescher, 2006). Excess ceramide is detrimental to the parasite (Pankova-Kholmyansky et al., 2003). Sphingolipid-enriched membrane micro-domains (SEMs) were glycosylphosphatidylinositol (GPI)-anchored proteins found in cell membrane and involved in various membrane functions. A primary function of SEMs is thought to be to regulate protein interactions by their ability to selectively recruit or exclude proteins as well as their ability to cluster into larger platforms (Manes et al., 2003). Interestingly, in a recent study on Cryptosporidium parasite, SEMs were found to have a role in facilitating parasite attachment to host cellular membrane and hence affecting their infectivity. They used an in vitro model of human biliary cryptosporidiosis, demonstrated that C. parvum infection triggers the clustering of SEM components at infection sites. Thus, disruption of SEM components or inhibition of SEM platform formation decreases Cryptosporidium attachment to and entry of cultured cholangiocytes. They reported also that clustering of SEM components at infection sites appears to be involved in aggregation of Gal/GalNAc-associated membrane
receptors and Cryptosporidium-induced activation of the PI-3K/Cdc42/actin signalling pathway, processes associated with parasite attachment to host cells and subsequent cellular entry. Thus, SEMs are required for C. parvum attachment to and entry of host cells, likely via clustering of membrane-binding proteins and facilitating of C. parvum-induced actin remodelling at infection sites via activation of the PI-3K/Cdc42 signalling pathway (Nelson et al, 2006). Since mefloquine proved a potent sphingomyelinase enzyme activator (Pankova-Kholmynsky et al, 2003). Theoretically it can affect SEMs in which sphingomyelin is a basic constituent (Manes et al, 2003) and consequently hinder the ability of Cryptosporidium parasite to attach, infect and form the tubulovesicular network necessary for its biology. We conclude that mefloquine is an effective, well characterized and FDA approved alternative treatment for C. parvum infection. It showed a higher activity than the NTZ which is the only FDA approved for treatment of C. parvum infection. More large scale studies are needed to illustrate its dose response relationship using multiple doses regimens, performance and limitations on immunocompromised population, synergistic effect with already approved drugs, mechanism of action on Cryptosporidium parasite and its possible role in chemophylaxis specially for high risk individuals. Clinical trials could be instantly and effortlessly designed, approved and executed as it is already marketed drug.

References


Nelson, JB, O’Hara, SP, Small, AJ, Tietz, PS,


 Explanation of figures

 Fig.1: Cryptosporidium parvum oocysts count in immunocompetent groups for each individual mouse.

 Fig. 2: Cryptosporidium parvum oocysts count in immunocompromized groups as recorded for each individual mouse.

 Fig. 3: Mean oocyst reduction rate of NTZ and mefloquine immunocompetent and immunocompromized mice.

 Fig. 4: Histopathological changes of small intestine of studied groups A&B: Non infected control mice tissue showing normal villi structure and length, no inflammatory reaction. C &D: Infected non treated mice tissue showing acute inflammatory cells infiltrations with sever villous atrophy E,F&G: Mefloquine treated mice tissue showing mild to moderate acute inflammatory cells infiltrations with villous widening H& I : NTZ treated mice tissue showing moderate to marked acute inflammatory cells infiltrations with villous widening.